Millions of people take a proton pump inhibitor every day to control heartburn, acid reflux, or ulcers, often for years at a stretch without ever revisiting whether they still need it. A growing body of research has started asking what that many years of acid suppression does to organs far from the stomach, and two answers keep surfacing: measurable increases in chronic kidney disease and, in some populations, a higher rate of dementia diagnoses. Neither finding proves the pills cause either condition, but both have been consistent enough to change how doctors think about long-term prescriptions. The drugs are not disappearing from medicine cabinets any time soon, so the more useful question for most long-term users is not whether to panic, but whether the original reason for starting the pill still applies.
What a Proton Pump Inhibitor Actually Does in the Stomach
These drugs work by shutting down the pumps in the stomach lining that produce acid, cutting acid output far more completely and for far longer than older heartburn remedies ever could. That makes them extremely effective at healing ulcers and controlling severe reflux, which is why they became some of the most widely prescribed drugs in the world within a few years of reaching pharmacy shelves. The tradeoff is that stomach acid does more than digest food; it also helps the body absorb certain minerals and vitamins and acts as a barrier against some bacteria, so suppressing it for years at a time changes more than just symptoms. Reduced acid has been tied separately to lower absorption of vitamin B12, magnesium, and calcium, and to shifts in the population of bacteria living in the gut, effects that researchers now treat as the likely starting point for some of the longer-term risks under study.
How Millions of People End Up Taking These Pills Long-Term
Proton pump inhibitors are commonly sold both over the counter and by prescription, and many patients start on a short course for an acute flare-up of heartburn only to stay on the medication indefinitely because it works and stopping brings symptoms back. Guidelines have generally called for periodic reassessment of whether a patient still needs the drug, but in practice renewal often happens automatically alongside other refills, with few formal check-ins about whether a lower dose, an alternative drug, or no drug at all might work just as well. That pattern of open-ended use is exactly the exposure researchers have been trying to study, since the risks in question tend to show up only after years of continuous use rather than after a short course.
The Kidney Signal Turning Up in Long-Term Users
A 2025 systematic review pooling data from prospective cohorts and cross-sectional studies found statistically significant associations between long-term proton pump inhibitor use and several adverse outcomes, chronic kidney disease among them, particularly in older adults and people with existing health conditions, according to a systematic review of the accumulated evidence. The proposed mechanisms include chronic, low-grade kidney inflammation that can develop silently over years before showing up in standard blood tests, along with a documented but less common acute kidney injury that can follow directly after starting the drug. The review’s authors were careful to note that confounding factors, since long-term PPI users are often older and sicker to begin with, make it hard to say how much of the kidney damage is driven by the drug itself versus the health problems that led to a long prescription in the first place.
A Dementia Risk That Looks Bigger in Some Populations Than Others
The dementia question has produced a messier picture. A focused review of the drug pantoprazole and cognitive decline found that observational studies conducted in Asian populations tended to report a meaningfully increased risk of dementia among long-term users, while similar studies conducted in Western populations showed inconsistent or null results, according to a 2025 review focused specifically on that drug and dementia risk. Proposed biological explanations include a possible role in amyloid-beta buildup in the brain, chronic vitamin B12 deficiency from reduced acid absorption, and effects on blood vessel lining that could compound over years, though none of these mechanisms has been proven to directly cause dementia in humans rather than simply correlating with it.
Why Deprescribing Is Becoming the Default Advice
None of this evidence amounts to a warning that short-term or occasional use is dangerous, and doctors generally agree the drugs remain the right choice for serious conditions like erosive esophagitis or a documented ulcer. What has shifted is the default assumption around renewal: rather than treating an existing prescription as permanent, more clinicians are now building in periodic reassessments, trying step-down doses, or switching patients to less potent acid reducers once the original flare-up has resolved. For patients who have been on the same pill for years without a recent conversation about whether they still need it, the accumulating kidney and cognitive data is less a reason for alarm than a reason to ask. That conversation typically involves a doctor or pharmacist reviewing the original diagnosis, checking recent kidney function tests, and weighing a trial reduction in dose against the near-certainty that heartburn symptoms will return in some form once acid suppression eases, which is often the real reason so many prescriptions simply continue unexamined for years.
This article was produced with the assistance of AI and reviewed by Morning Overview editors.
More from Morning Overview
